AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
Thu 20 Mar 25, 08:05 PMVelan Capital Investment Management LP Boosts Stake in Alimera Sciences Inc
Thu 03 Aug 23, 11:03 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -44.29600M | -33.27600M | -28.79400M | -22.42500M | -21.09200M |
| Minority interest | - | - | - | - | - |
| Net income | -44.33700M | -36.11000M | -31.87800M | -25.80300M | -21.09200M |
| Selling general administrative | 13.86M | 12.46M | 10.14M | 6.22M | 4.90M |
| Selling and marketing expenses | 43.25M | 29.06M | 22.11M | 18.06M | 13.65M |
| Gross profit | 27.04M | 18.81M | 11.23M | 9.27M | 2.94M |
| Reconciled depreciation | 1.19M | 0.54M | 0.53M | 0.58M | 1.25M |
| Ebit | -39.00700M | -29.45100M | -25.27500M | -19.16200M | -19.87200M |
| Ebitda | -39.01700M | -29.67900M | -25.23000M | -18.81100M | -18.62400M |
| Depreciation and amortization | -0.01000M | -0.22800M | 0.04M | 0.35M | 1.25M |
| Non operating income net other | -1.23800M | -0.22800M | - | - | - |
| Operating income | -39.00700M | -29.45100M | -25.27500M | -19.16200M | -17.78200M |
| Other operating expenses | 80.42M | 58.91M | 43.49M | 34.61M | 28.22M |
| Interest expense | 4.05M | 3.60M | 3.56M | 3.61M | 1.80M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | 3.61M | 1.56M |
| Net interest income | -4.05100M | -3.59700M | -3.56400M | -3.60900M | -1.80200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.04M | 2.83M | 3.08M | 3.38M | -1.50800M |
| Total revenue | 41.42M | 29.46M | 18.21M | 15.45M | 8.27M |
| Total operating expenses | 66.05M | 48.26M | 36.51M | 28.43M | 22.88M |
| Cost of revenue | 14.37M | 10.65M | 6.98M | 6.17M | 5.33M |
| Total other income expense net | -5.28900M | -3.82500M | -3.51900M | -3.26300M | 0.65M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -44.29600M | -33.27600M | -28.79400M | -22.42500M | -21.09200M |
| Net income applicable to common shares | -44.29600M | -33.27600M | -28.79400M | -30.20800M | -29.91500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 78.05M | 67.86M | 62.54M | 86.46M | 67.92M |
| Intangible assets | 2.12M | 2.50M | 2.30M | 2.61M | 2.91M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.10M | 2.02M | 3.23M | 2.24M | 2.31M |
| Total liab | 59.17M | 53.55M | 42.45M | 37.43M | 36.96M |
| Total stockholder equity | 18.88M | 14.30M | 20.10M | 49.03M | 30.96M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 14.73M | 10.53M | 8.16M | 5.95M | 3.54M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -320.88900M | -274.22500M | -229.92900M | -196.65300M | -167.85900M |
| Other liab | - | - | 0.38M | - | 0.00400M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 46.73M | 42.02M | 43.93M | 74.39M | 45.30M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 16.97M | 12.40M | 10.57M | 6.61M | 6.71M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -3.94900M | -2.10300M | -12.44000M | -43.56700M | -15.05900M |
| Short term debt | 0.56M | 0.34M | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 42.78M | 39.92M | 31.49M | 30.83M | 30.24M |
| Other stockholder equity | 339.65M | 288.36M | 250.06M | 245.74M | 130.91M |
| Property plant equipment | - | 1.68M | 1.19M | 0.63M | 0.68M |
| Total current assets | 71.73M | 62.45M | 59.05M | 83.22M | 64.33M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 11.81M | 17.80M | 46.42M | 28.05M |
| Short term investments | - | - | - | 0.00000M | 9.29M |
| Net receivables | 9.74M | 6.62M | 4.23M | 2.68M | 2.84M |
| Long term debt | 40.52M | 39.92M | 31.49M | 30.83M | 30.24M |
| Inventory | 13.16M | 11.79M | 7.66M | 3.91M | 4.60M |
| Accounts payable | 1.67M | 1.53M | 2.41M | 0.65M | 3.17M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.09M | 0.15M | -0.05200M | -0.07100M | -0.01900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.02M | 0.01M | 0.01M | 0.01M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -274.22500M | -229.92900M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.27M | 1.23M | - | - | 2.91M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6.32M | 5.41M | 3.49M | 3.23M | 3.59M |
| Capital lease obligations | 0.56M | 0.34M | - | - | - |
| Long term debt total | - | 39.92M | 31.49M | - | 30.24M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1.87200M | -0.62700M | 9.12M | -11.98100M | -9.28400M |
| Change to liabilities | 1.51M | 4.27M | -2.00200M | -0.77300M | 1.91M |
| Total cashflows from investing activities | -1.87200M | -0.62700M | 9.12M | -11.98100M | -1.55800M |
| Net borrowings | 6.54M | 10.00M | 10.00M | 10.00M | 25.00M |
| Total cash from financing activities | 40.85M | 0.58M | 44.41M | 65.53M | 27.41M |
| Change to operating activities | 4.04M | 1.69M | 2.32M | -2.11600M | -1.07100M |
| Net income | -44.29600M | -33.27600M | -28.79400M | -22.42500M | -21.09200M |
| Change in cash | -1.91200M | -30.46300M | 29.09M | 28.02M | 5.93M |
| Begin period cash flow | 43.93M | 74.39M | 45.30M | 17.28M | 11.35M |
| End period cash flow | 42.02M | 43.93M | 74.39M | 45.30M | 17.28M |
| Total cash from operating activities | -40.74800M | -30.43200M | -24.45600M | -25.52300M | -19.92400M |
| Issuance of capital stock | 34.40M | 0.00000M | 44.72M | 65.52M | 3.98M |
| Depreciation | 1.19M | 0.54M | 0.53M | 0.58M | 1.25M |
| Other cashflows from investing activities | -1.00000M | - | - | -9.28400M | 0.00400M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -6.07300M | -5.19400M | -0.62000M | -1.83900M | -4.75700M |
| Change to account receivables | -2.42100M | -1.55300M | 0.15M | -1.52800M | -0.54100M |
| Sale purchase of stock | 0.05M | 0.04M | 0.03M | 65.53M | 3.98M |
| Other cashflows from financing activities | 36.40M | 0.55M | -0.34700M | 14.38M | 46.15M |
| Change to netincome | 6.93M | 5.78M | 3.97M | 2.58M | 4.38M |
| Capital expenditures | 1.87M | 0.63M | 0.17M | 2.70M | 1.56M |
| Change receivables | -2.42100M | -1.55300M | - | - | - |
| Cash flows other operating | 3.21M | -0.68800M | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -1.76800M | -30.47400M | - | - | - |
| Change in working capital | -5.76300M | -3.46900M | -0.08600M | -6.23500M | -4.45500M |
| Stock based compensation | 3.99M | 3.66M | 2.06M | 0.46M | 0.22M |
| Other non cash items | 4.13M | 2.10M | 1.84M | 2.09M | 2.94M |
| Free cash flow | -42.62000M | -31.05900M | -24.62300M | -28.22000M | -21.48600M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TELA Tela Bio Inc |
-0.0432 4.88% | 0.84 | - | - | 2.07 | 6.42 | 1.98 | -2.8456 |
| ABT Abbott Laboratories |
-2.1 1.86% | 110.55 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-7.27 1.99% | 358.65 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-1.45 1.59% | 89.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-1.94 2.70% | 69.96 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
1 Great Valley Parkway, Malvern, PA, United States, 19355
| Name | Title | Year Born |
|---|---|---|
| Mr. Antony Koblish | Co-founder, Pres, CEO & Director | 1966 |
| Dr. E. Skott Greenhalgh Ph.D. | Chief Technology Officer | 1968 |
| Mr. Peter C. Murphy | Chief Commercial Officer | 1973 |
| Mr. Roberto E. Cuca J.D. | CFO & COO | 1968 |
| Ms. Megan Smeykal | VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer | 1976 |
| Mr. D. Taylor Ocasio | Gen. Counsel | NA |
| Mr. Christopher H. Smith | Sr. VP of Sales | 1961 |
| Ms. Jennifer Lou Armstrong | Sr. VP of HR | 1970 |
| Mr. Michael Leonard | Sr. VP of Technical Operations | NA |
| Mr. Paul Talmo | Chief Strategic Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...